Hostname: page-component-78c5997874-t5tsf Total loading time: 0 Render date: 2024-11-10T06:02:05.591Z Has data issue: false hasContentIssue false

Subjective response to neuroleptics and outcome in schizophrenia: a re-examination comparing two measures

Published online by Cambridge University Press:  09 July 2009

T. P. Hogan*
Affiliation:
Queen Street Mental Health Centre and the Department of Psychiatry, University of Toronto, Canada
A. G. Awad
Affiliation:
Queen Street Mental Health Centre and the Department of Psychiatry, University of Toronto, Canada
*
1Address for correspondence: Mr T. P. Hogan, Psychology and Biometrics Section, Schizophrenia Research Program, Queen Street Mental Health Centre, 1001 Queen Street West, Toronto, Canada, M6J 1H4.

Synopsis

The schizophrenic patient's early psychological response to neuroleptic treatment has been demonstrated to be a significant predictor of treatment response. The validity of the construct of subjective response is evaluated by comparison of two measures. Fifty-five recently admitted and unmedicated schizophrenic patients were randomly allocated to chlorpromazine or haloperidol. Subjective responses at 24 and 48 hours as assessed by two different scales, the Van Putten & May scale and the self-administered Drug Attitude Inventory, were strongly correlated with outcome at three weeks. Early emergence of extrapyramidal symptoms was not related to subjective response, but dysphoric patients had a greater incidence of EPS by the end of treatment than did non-dysphoric patients. The two measures showed high concordance in identification of early drug dysphoria.

Type
Original Articles
Copyright
Copyright © Cambridge University Press 1992

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Baldessarini, R. J., Katz, B. & Cotton, P. (1984). Dissimilar dosing with high potency and low potency neuroleptics. American Journal of Psychiatry 141, 748752.Google ScholarPubMed
Carpenter, W. T., Strauss, J. S. & Bartko, J. J. (1973). Flexible system for the diagnosis of schizophrenia: report from the WHO International Pilot Study of Schizophrenia. Science 182, 12751278.CrossRefGoogle ScholarPubMed
Cicchetti, D. V. & Prusoff, B. A. (1983). Reliability of depression and associated clinical syndromes. Archives of General Psychiatry 40, 987990.CrossRefGoogle Scholar
Endicott, J., Spitzer, R. L. & Fleiss, J. L. (1976). The Global Assessment Scale: a procedure for measuring overall severity of psychiatric disturbance. Archives of General Psychiatry 33, 766771.CrossRefGoogle Scholar
Feighner, J. P., Robins, E. & Guze, S. B. (1972). Diagnostic criteria for use in psychiatric research. Archives of General Psychiatry 26, 5763.CrossRefGoogle ScholarPubMed
Guy, W. (1976). Dosage Record and Treatment Emergent Scale (DOTES). In ECDEU Assessment Manual for Psycho-pharmacology (ed. Guy, W.), pp. 223224. MD, DHEW Publication No. (ADM) 76–337: Rockville.Google Scholar
Hogan, T. P., Awad, A. G. & Eastwood, M. R. (1983). A self-report scale predictive of drug compliance in schizophrenics: Reliability and discriminative validity. Psychological Medicine 13, 177183.CrossRefGoogle ScholarPubMed
Kane, J. M. (1989). The current status of neuroleptic therapy. Journal of Clinical Psychiatry 50, 322328.Google ScholarPubMed
Kolakowska, T. (1980). Brief Psychiatric Rating Scale: glossaries and rating instructions. Unpublished manuscript, available from the author, Department of Psychiatry, University of Oxford, England.Google Scholar
May, P. R. A., Van Putten, T. & Yale, C. (1976). Predicting individual responses to drug treatment in schizophrenia: a test dose model. Journal of Nervous and Mental Disease 162, 177183.CrossRefGoogle ScholarPubMed
May, P. R. A., Van Putten, T.Jenden, D. J., Yale, C., Dixon, W. J. & Goldstein, M. J. (1981). Prognosis in schizophrenia: individual differences in psychological response to a test dose of antipsychotic drug and their relationship to blood and saliva levels and treatment outcome. Comprehensive Psychiatry 22, 147152.CrossRefGoogle ScholarPubMed
Overall, J. E. & Gorham, d. R. (1961). The Brief Psychiatric Rating Scale. Psychological Reports 10, 799812.CrossRefGoogle Scholar
Overall, J. E., Hollister, L. E. & Dalal, S. N. (1967). Psychiatric drug research: sample size requirements for one vs. two raters. Archives of General Psychiatry 16, 152161.CrossRefGoogle ScholarPubMed
Shrout, P. E. & Fleiss, J. L. (1979). Intraclass correlations: uses in assessing rater reliability. Psychological Bulletin 86, 420428.CrossRefGoogle ScholarPubMed
Singh, M. M. (1976). Dysphoric response to neuroleptic treatment in schizophrenia and its prognostic significance. Diseases of the Nervous System 37, 191196.Google ScholarPubMed
Singh, M. M. & Kay, S. R. (1979). Dysphoric response to neuroleptic treatment in schizophrenia: its relationship to autonomic arousal and prognosis. Biological Psychiatry 14, 277294.Google ScholarPubMed
Van Putten, T. (1983). The clinical management of non-compliance. In The Chronic Psychiatric Patient in the Community: Principles of Treatment (ed. Barofsky, I. and Budson, R. D.), pp. 383395. Spectrum Publications: Jamaica, New York.CrossRefGoogle Scholar
Van Putten, T. & May, P. R. A. (1978). Subjective response as a predictor of outcome in pharmacotherapy. Archives of General Psychiatry 35, 477480.CrossRefGoogle ScholarPubMed
Van Putten, T., May, P. R. A., Jenden, D. J., Cho, A. K. & Yale, C. (1980 a). Plasma and saliva levels of chlorpromazine and subjective response. American Journal of Psychiatry 137, 12411242.Google ScholarPubMed
Van Putten, T., May, P. R. A. & Marder, S. R. (1980 b). Subjective responses to thiothixene and chlorpromazine. Psychopharmacology Bulletin 16, 3638.Google Scholar
Van Putten, T., May, P. R. A., Marder, S. R. & Wittam, L. (1981). Subjective response to antipsychotic drugs. Archives of General Psychiatry 38, 187190.CrossRefGoogle ScholarPubMed